文献速递头颈甲状腺与浅表技术与安全US

淋巴与静脉超声造影联合评估甲状腺乳头状癌颈部淋巴结转移的初步研究

Combination of Lymphatic and Intravenous Contrast-Enhanced Ultrasound for Evaluation of Cervical Lymph Node Metastasis from Papillary Thyroid Carcinoma: A Preliminary Study.
PubMed 文献 · Ultrasound Med Biol · 2020-11-04

前瞻性纳入2018年11月至2019年3月24例甲状腺乳头状癌连续患者,均行常规超声、淋巴超声造影(LCEUS)和静脉超声造影(IVCEUS),以病理为金标准。LCEUS诊断颈部淋巴结转移的AUC为0.850,高于IVCEUS的0.692和常规超声的0.581;两者联合AUC最高为0.863。

要点

  • LCEUS诊断甲状腺乳头状癌颈部淋巴结转移的AUC为0.850,优于IVCEUS(0.692)和常规超声(0.581)。
  • LCEUS诊断转移的特征性征象为灌注缺损(94.9%)和亮环中断(71.8%)。
  • LCEUS与IVCEUS联合诊断价值最高,AUC为0.863。

核心结论

  • LCEUS对甲状腺乳头状癌颈部淋巴结转移的诊断价值高于IVCEUS和常规超声。
  • LCEUS与IVCEUS联合具有最高的诊断价值。

研究设计与样本

  • 前瞻性研究,2018年11月至2019年3月连续纳入24例甲状腺乳头状癌患者。
  • 所有患者均行常规超声、LCEUS和IVCEUS检查,以病理为金标准。
  • LCEUS经甲状腺实质注射造影剂后,淋巴管和淋巴结呈高增强显示。

关键影像表现/征象

  • 良性淋巴结在LCEUS上显示完整亮环(100%)和均匀灌注(88.9%),在IVCEUS上显示离心性灌注(66.7%)和均匀增强(88.9%)。
  • LCEUS诊断转移的特征性征象为灌注缺损(94.9%)和亮环中断(71.8%)。
  • IVCEUS上转移淋巴结表现为向心性灌注(59.0%)和不均匀增强(59.0%)。

诊断标准与关键数值

  • LCEUS诊断颈部淋巴结转移的AUC为0.850(95%CI:0.682-1.000)。
  • IVCEUS诊断颈部淋巴结转移的AUC为0.692(95%CI:0.494-0.890)。
  • 常规超声诊断颈部淋巴结转移的AUC为0.581(95%CI:0.367-0.796)。
  • LCEUS与IVCEUS联合诊断的AUC为0.863(95%CI:0.696-1.000)。

临床应用与阅片要点

  • 灌注缺损与髓质内转移灶相关,亮环中断与边缘窦肿瘤种植相关(所有p值<0.05)。
  • LCEUS可作为评估甲状腺乳头状癌颈部淋巴结转移的补充手段,联合IVCEUS可提高诊断价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The aim of this prospective study was to evaluate the value of the combination of lymphatic contrast-enhanced ultrasound (LCEUS) and intravenous contrast-enhanced ultrasound (IVCEUS) for the identification of cervical lymph node metastasis (CLNM) from papillary thyroid carcinoma (PTC). From November 2018 to March 2019, 24 consecutive patients with PTC were evaluated. All patients underwent routine US, LCEUS and IVCEUS. Pathology was used as the gold standard. After injection of a contrast agent into the thyroid parenchyma, lymphatic vessels and lymph nodes (LNs) could be exclusively displayed as hyper-enhancement on LCEUS. Benign LNs displayed a complete bright ring (100%) and homogeneous perfusion (88.9%) on LCEUS, while displaying centrifugal perfusion (66.7%) and homogenous enhancement (88.9%) on IVCEUS. Perfusion defects (94.9%) and interruption of the bright ring (71.8%) were the two characteristic LCEUS signs for diagnosing CLNM. On IVCEUS, CLNM appeared as centripetal perfusion (59.0%) and heterogeneous enhancement (59.0%). After comparison with pathology, perfusion defect was correlated to the metastatic foci in the medulla and interruption of the bright ring to the tumor seeding in the marginal sinus (all p values <0.05). LCEUS had more value (area under the receiver operating characteristic curve [AUC] = 0.850, 95% confidence interval [CI]: 0.682-1.000) in diagnosing CLNM than IVCEUS (AUC = 0.692, 95% CI: 0.494-0.890) and routine US (AUC = 0.581, 95% CI: 0.367-0.796). The combination of LCEUS and IVCEUS has the highest diagnostic value (AUC = 0.863, 95% CI: 0.696-1.000). LCEUS had higher diagnostic value than IVCEUS and US for CLNM from PTC. The combination of LCEUS and IVCEUS has the highest diagnostic value for CLNM.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Wei Y, Yu MA, Niu Y, et al. Combination of Lymphatic and Intravenous Contrast-Enhanced Ultrasound for Evaluation of Cervical Lymph Node Metastasis from Papillary Thyroid Carcinoma: A Preliminary Study. Ultrasound Med Biol. 2020. PMID: 33158634. doi:10.1016/j.ultrasmedbio.2020.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。